Mirabegron

potential off target effects and uses beyond the bladder

Nodi Dehvari, Edilson Dantas da Silva Junior, Tore Bengtsson, Dana Sabine Hutchinson

Research output: Contribution to journalReview ArticleResearchpeer-review

10 Citations (Scopus)

Abstract

The β3-adrenoceptor was initially an attractive target for several pharmaceutical companies due to its high expression in rodent adipose tissue, where its activation resulted in decreased adiposity and improved metabolic outputs (such as glucose handling) in animal models of obesity and Type 2 diabetes. However, several drugs acting at the β3-adrenoceptor failed in clinical trials. This was thought to be due to their lack of efficacy at the human receptor. Recently, mirabegron, a β3-adrenoceptor agonist with human efficacy, was approved in North America, Europe, Japan and Australia for the treatment of overactive bladder syndrome. There are indications that mirabegron may act at other receptors/targets, but whether they have any clinical relevance is relatively unknown. Besides overactive bladder syndrome, mirabegron may have other uses such as in the treatment of heart failure or metabolic disease. This review gives an overview of the off-target effects of mirabegron and its potential use in the treatment of other diseases. Linked Articles: This article is part of a themed section on Molecular Pharmacology of GPCRs. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.21/issuetoc.

Original languageEnglish
Pages (from-to)4072-4082
Number of pages11
JournalBritish Journal of Pharmacology
Volume175
Issue number21
DOIs
Publication statusPublished - 1 Nov 2018

Cite this

Dehvari, Nodi ; Dantas da Silva Junior, Edilson ; Bengtsson, Tore ; Hutchinson, Dana Sabine. / Mirabegron : potential off target effects and uses beyond the bladder. In: British Journal of Pharmacology. 2018 ; Vol. 175, No. 21. pp. 4072-4082.
@article{7fa8eb97b7394c4eae19ddd623790b22,
title = "Mirabegron: potential off target effects and uses beyond the bladder",
abstract = "The β3-adrenoceptor was initially an attractive target for several pharmaceutical companies due to its high expression in rodent adipose tissue, where its activation resulted in decreased adiposity and improved metabolic outputs (such as glucose handling) in animal models of obesity and Type 2 diabetes. However, several drugs acting at the β3-adrenoceptor failed in clinical trials. This was thought to be due to their lack of efficacy at the human receptor. Recently, mirabegron, a β3-adrenoceptor agonist with human efficacy, was approved in North America, Europe, Japan and Australia for the treatment of overactive bladder syndrome. There are indications that mirabegron may act at other receptors/targets, but whether they have any clinical relevance is relatively unknown. Besides overactive bladder syndrome, mirabegron may have other uses such as in the treatment of heart failure or metabolic disease. This review gives an overview of the off-target effects of mirabegron and its potential use in the treatment of other diseases. Linked Articles: This article is part of a themed section on Molecular Pharmacology of GPCRs. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.21/issuetoc.",
author = "Nodi Dehvari and {Dantas da Silva Junior}, Edilson and Tore Bengtsson and Hutchinson, {Dana Sabine}",
year = "2018",
month = "11",
day = "1",
doi = "10.1111/bph.14121",
language = "English",
volume = "175",
pages = "4072--4082",
journal = "British Journal of Pharmacology",
issn = "1476-5381",
publisher = "Wiley-Blackwell",
number = "21",

}

Mirabegron : potential off target effects and uses beyond the bladder. / Dehvari, Nodi; Dantas da Silva Junior, Edilson; Bengtsson, Tore; Hutchinson, Dana Sabine.

In: British Journal of Pharmacology, Vol. 175, No. 21, 01.11.2018, p. 4072-4082.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Mirabegron

T2 - potential off target effects and uses beyond the bladder

AU - Dehvari, Nodi

AU - Dantas da Silva Junior, Edilson

AU - Bengtsson, Tore

AU - Hutchinson, Dana Sabine

PY - 2018/11/1

Y1 - 2018/11/1

N2 - The β3-adrenoceptor was initially an attractive target for several pharmaceutical companies due to its high expression in rodent adipose tissue, where its activation resulted in decreased adiposity and improved metabolic outputs (such as glucose handling) in animal models of obesity and Type 2 diabetes. However, several drugs acting at the β3-adrenoceptor failed in clinical trials. This was thought to be due to their lack of efficacy at the human receptor. Recently, mirabegron, a β3-adrenoceptor agonist with human efficacy, was approved in North America, Europe, Japan and Australia for the treatment of overactive bladder syndrome. There are indications that mirabegron may act at other receptors/targets, but whether they have any clinical relevance is relatively unknown. Besides overactive bladder syndrome, mirabegron may have other uses such as in the treatment of heart failure or metabolic disease. This review gives an overview of the off-target effects of mirabegron and its potential use in the treatment of other diseases. Linked Articles: This article is part of a themed section on Molecular Pharmacology of GPCRs. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.21/issuetoc.

AB - The β3-adrenoceptor was initially an attractive target for several pharmaceutical companies due to its high expression in rodent adipose tissue, where its activation resulted in decreased adiposity and improved metabolic outputs (such as glucose handling) in animal models of obesity and Type 2 diabetes. However, several drugs acting at the β3-adrenoceptor failed in clinical trials. This was thought to be due to their lack of efficacy at the human receptor. Recently, mirabegron, a β3-adrenoceptor agonist with human efficacy, was approved in North America, Europe, Japan and Australia for the treatment of overactive bladder syndrome. There are indications that mirabegron may act at other receptors/targets, but whether they have any clinical relevance is relatively unknown. Besides overactive bladder syndrome, mirabegron may have other uses such as in the treatment of heart failure or metabolic disease. This review gives an overview of the off-target effects of mirabegron and its potential use in the treatment of other diseases. Linked Articles: This article is part of a themed section on Molecular Pharmacology of GPCRs. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.21/issuetoc.

UR - http://www.scopus.com/inward/record.url?scp=85040745117&partnerID=8YFLogxK

U2 - 10.1111/bph.14121

DO - 10.1111/bph.14121

M3 - Review Article

VL - 175

SP - 4072

EP - 4082

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 1476-5381

IS - 21

ER -